AREDS / AREDS2
Landmark NIH trials demonstrating that a specific antioxidant and zinc formulation slows progression of intermediate to advanced age-related macular degeneration.
Also: AREDS, AREDS2, Age-Related Eye Disease Study
AREDS (2001) showed 25% risk reduction in advanced AMD with vitamin C 500 mg, vitamin E 400 IU, β-carotene 15 mg, zinc 80 mg, and copper 2 mg daily over 5 years. AREDS2 (2013) substituted lutein 10 mg + zeaxanthin 2 mg for β-carotene (which increased lung cancer risk in smokers) and tested omega-3 addition, which did not provide further benefit. The AREDS2 formulation is the current standard supplement for intermediate AMD.
How one textbook covers it
Modern Nutrition in Health and Disease, 12th ed. — Ch 100: Age-Related Eye Diseases
AREDS (2001) showed 25% risk reduction in advanced AMD with vitamin C 500 mg, vitamin E 400 IU, β-carotene 15 mg, zinc 80 mg, and copper 2 mg daily over 5 years. AREDS2 (2013) substituted lutein 10 mg + zeaxanthin 2 mg for β-carotene (which increased lung cancer risk in smokers) and tested omega-3 addition, which did not provide further benefit. The AREDS2 formulation is the current standard supplement for intermediate AMD.
Related terms
AMD, Carotenoids, Lutein, Zinc